


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 471/04, 519/00, A61K 31/435 // (C07D 471/04, 221/00, 209/00) (C07D 519/00, 471/00, 471/00)		A1	(11) International Publication Number: WO 96/16964 (43) International Publication Date: 6 June 1996 (06.06.96)
(21) International Application Number: PCT/EP95/04247 (22) International Filing Date: 30 October 1995 (30.10.95) (30) Priority Data: 9423997.7 28 November 1994 (28.11.94) GB		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
<p>(71) Applicant (for all designated States except US): PHARMACIA S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milan (IT).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BUZZETTI, Franco [IT/IT]; Via della Gallarana, 4, I-20052 Monza (IT). BRASCA, Gabriella, Maria [IT/IT]; Via Dante Alighieri, 15, I-20090 Cusago (IT). LONGO, Antonio [IT/IT]; Via N.A. Porpora, 160, I-20131 Milan (IT). BALLINARI, Dario [IT/IT]; Via C. Jannozzi, 8, I-20097 San Donato Milanese (IT).</p>		<p>Published With international search report.</p>	
<p>(54) Title: SUBSTITUTED 3-ARYLIDENE-7-AZAOXINDOLE COMPOUNDS AND PROCESS FOR THEIR PREPARATION</p> <p>(57) Abstract</p> <p>The present invention relates to compound of formula (I) wherein A is benzene, naphthalene, 5,6,7,8-tetrahydronaphthalene, quinoline, isoquinoline, indole or 7-azaindole; R₁ is -H, -CN, -SO₂R₄, -SO₂NHR₅, (i), -COOR₆, -CONHCH₂(CHOH)_nCH₂OH, (ii), -NR₇R₈, -N(CH₂CH₂OH)₂, -NHCH₂(CHOH)_nCH₂OH, -NHCONH₂, -NH-C(NH₂)=NH, -NHCO(CHOH)_nCH₂OH, (iii), -NHSO₂R₉, -OR₁₀, -OCH₂(CHOH)_nCH₂OH, -OOC(CHOH)_nCH₂OH, -OPO(OH)₂, -CH₂NH₂, -C(NH₂)=NH, -CH₂NHC(NH₂)=NH, (iv), -CH₂OH, -CH₂OOC(CHOH)_nCH₂OH, -CH₂OPO(OH)₂ or -PO(OH)₂; R₂ is C₁-C₆ alkyl, halogen, or hydroxy; R₃ is -H or C₁-C₆ alkyl; R₄ is -H, C₁-C₆ alkyl or -CH₂(CHOH)_nCH₂OH; R₅ is -H, C₁-C₆ alkyl, -CH₂(CHOH)_nCH₂OH or -(CH₂)_mNMe₂; R₆ is -H, C₁-C₆ alkyl or -CH₂(CHOH)_nCH₂OH; each of R₇ and R₈ independently is -H or C₁-C₆ alkyl; R₉ is methyl or tolyl; R₁₀ is -H, C₁-C₆ alkyl or C₂-C₆ alkanoyl; Z is >CH₂, >O, >NH or >NCH₂CH₂OH; n is zero or 1; m is 2 or 3; p is 1, 2 or 3; q is zero, 1 or 2; and the pharmaceutically acceptable salt thereof, for use as tyrosine kinase inhibitors.</p>			



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

WO 96/16964


PCT/EP95/04247

-1-

**SUBSTITUTED 3-ARYLIDENE-7-AZAOXINDOLE COMPOUNDS AND PROCESS
FOR THEIR PREPARATION**

5 The present invention relates to 3-arylidene-7-azaoxindole compounds, to a process for their preparation, to pharmaceutical compositions containing them and to their use as therapeutic agents.

10 The present invention provides compounds having the following general formula (I)



wherein

15 A is benzene, naphthalene, 5,6,7,8,-tetrahydronaphthalene, quinoline, isoquinoline, indole or 7-azaindole;

R₁ is -H, -CN, -SO₃R₄, -SO₂NHR₅, -COOR₆,

-CONC₆H₄Z, -NR₇R₈, -N(CH₂CH₂OH)₂,
-NHCH₂(CHOH)_nCH₂OH, -NHCONH₂, -NH-C(NH₂)=NH,

-NHCO(CH₂)_p-N(C₆H₄Z), -NHSO₂R₉, -OR₁₀,

20 -OCH₂(CHOH)_nCH₂OH, -OOC(CHOH)_nCH₂OH, -OPO(OH)₂, -CH₂NH₂,

-C(NH₂)=NH, -CH₂NHC(NH₂)=NH,

WO 96/16964

PCT/EP95/04247

-2-

-CH₂OOC(CHOH)_nCH₂OH, -CH₂OPO(OH)₂ or -PO(OH)₂;

R₂ is C₁-C₆ alkyl, halogen, or hydroxy;

R₃ is -H or C₁-C₆ alkyl;

R₄ is -H, C₁-C₆ alkyl or -CH₂(CHOH)_nCH₂OH;

5 R₅ is -H, C₁-C₆ alkyl, -CH₂(CHOH)_nCH₂OH or -(CH₂)_mNMe₂;

R₆ is -H, C₁-C₆ alkyl or -CH₂(CHOH)_nCH₂OH;

each of R₁ and R₅ independently is -H or C₁-C₆ alkyl;

R₉ is methyl or tolyl;

R₁₀ is -H, C₁-C₆ alkyl or C₂-C₆ alkanoyl;

10 Z is >CH₂, >O, >NH or >NCH₂CH₂OH;

n is zero or 1;

m is 2 or 3;

p is 1, 2 or 3;

q is zero, 1 or 2;

15 and the pharmaceutically acceptable salt thereof.

The invention includes within its scope all the possible isomers, stereoisomers, in particular Z- and E-isomers, as well as the metabolites and the metabolic precursors or 20 bio-precursors (otherwise known as pro-drugs) of the compounds of formula (I).

The substituents R₁ and R₂ may be independently on either of the ring moieties when A is bicyclic.

The azaoxindolylidene substituent is preferably linked to 25 position 1 or 2 when A is naphthalene or 5,6,7,8-tetrahydronaphthalene, to position 4 or 5 when A is quinoline, to position 1 or 3 when A is isoquinoline, to position 3 when A is indole, or 7-azaindole.

The R₁ substituent with reference to the azaoxindolylidene 30 substituent is preferably linked to the other ring moiety

-3-

when A is naphthalene, 5,6,7,8-tetrahydronaphthalene, quinoline, isoquinoline, indole or azaindole.

The alkyl group and the alkyl moiety in the alkanoyl group may be branched or straight alkyl chains.

5 A C₁-C₆ alkyl group is preferably a C₁-C₄ alkyl group, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or t-butyl, in particular methyl or ethyl.

A C₂-C₆ alkanoyl group is preferably a C₂-C₃ alkanoyl group, in particular acetyl or propionyl.

10 A halogen is preferably fluorine, chlorine or bromine, in particular fluorine.

Pharmaceutically acceptable salts of the compounds of the invention include acid addition salts with inorganic, e.g. nitric, hydrochloric, hydrobromic, sulfuric, perchloric and

15 phosphoric acids or organic, e.g. acetic, trifluoroacetic, propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic and salicylic acids, and salts with inorganic, e.g. alkali metal, especially sodium or potassium, bases or alkaline-

20 earth metal, especially calcium or magnesium, bases or with organic bases, e.g. acyclic or cyclic amines, preferably triethylamine or piperidine.

As stated above, the present invention also includes within its scope pharmaceutically acceptable bio-precursors

25 (otherwise known as pro-drugs) of the compounds of formula (I), i.e. compounds which have a different formula to formula (I) above but which, nevertheless, upon administration to a human being are converted directly or indirectly in vivo into a compound of formula (I).

WO 96/16964


PCT/EP95/04247


-4-

Preferred compounds of the invention are the compounds of formula (I), wherein

A is benzene, 5,6,7,8-tetrahydronaphthalene, quinoline, indole or 7-azaindole;


5 R₁ is -H, -NH₂, -COOH, -CN, -SO₃H, -SO₂NH₂,



-CON  , -COOMe, -N(CH₂CH₂OH)₂, -NHCH₂CHOHCH₂OH,

-NHCONH₂, -NHC(NH₂)=NH, -NHCOCHOHCH₂OH,
 -NSO₂Me, -OCH₂CHOHCH₂OH, -OOCCH₂OH, -OOCCHOHCH₂OH, -OH,

-OMe, -OPO(OH)₂, -CH₂NH₂, -C(NH₂)=NH,



10 -CH₂OH, -OPO(OH)₂, -PO(OH)₂;

R₂ is C₁-C₆ alkyl or hydroxy;

R₃ is -H;

q is zero, 1 or 2;

and the azaoxindolylidene substituent is preferably linked

15 to position 1 or 2 when A is naphthalene or 5,6,7,8-

tetrahydronaphthalene, to position 4 or 5 when A is

quinoline, to position 3 when A is indole or 7-azaindole,

whereas the R₁ substituent is preferably linked to the

other ring moiety when A is bicyclic, and the

20 pharmaceutically acceptable salts thereof.

Examples of specific compounds of the invention are the following compounds, which, when appropriate may be either Z- or E-diastereomers or Z,E-mixtures of said

25 diastereomers:

WO 96/16964

PCT/EP95/04247

-5-

- 1) 3-[(3,5-di-tert-butyl-4-hydroxyphenyl)methylene]-7-azaoxindole;
- 2) 3-[(4-hydroxyphenyl)methylene]-7-azaoxindole;
- 3) 3-[4-(2,3-dihydroxypropoxy)phenylmethylene]-7-azaoxindole;
- 5 4) 3-[(4-methoxyphenyl)methylene]-7-azaoxindole;
- 5) 3-[(4-aminophenyl)methylene]-7-azaoxindole;
- 6) 3-[(4-diethanolaminophenyl)methylene]-7-azaoxindole;
- 7) 3-[(4-glyceroylamidophenyl)methylene]-7-azaoxindole;
- 10 8) 3-[4-(3-piperidinopropionylamino)phenyl)methylene]-7-azaoxindole;
- 9) 3-[(4-ureidophenyl)methylene]-7-azaoxindole;
- 10) 3-[(4-mesylaminophenyl)methylene]-7-azaoxindole;
- 11) 3-[(4-guanidinophenyl)methylene]-7-azaoxindole;
- 15 12) 3-[(4-sulfophenyl)methylene]-7-azaoxindole;
- 13) 3-[(4-N,N-piperazinylsulfamoylphenyl)methylene]-7-azaoxindole;
- 14) 3-[(4-sulfamoylphenyl)methylene]-7-azaoxindole;
- 15) 3-[(4-aminomethylphenyl)methylene]-7-azaoxindole;
- 20 16) 3-[(4-amidinophenyl)methylene]-7-azaoxindole;
- 17) 3-[(4-phosphonoxyphenyl)methylene]-7-azaoxindole;
- 18) 3-[(4-carboxyphenyl)methylene]-7-azaoxindole;
- 19) 3-[(4-carbomethoxyphenyl)methylene]-7-azaoxindole;
- 20) 3-[(4-hydroxymethylphenyl)methylene]-7-azaoxindole;
- 25 21) 3-[4-(2,3-dihydroxypropylamino)phenylmethylene]-7-azaoxindole;
- 22) 3-[(4-glycoloyloxyphenyl)methylene]-7-azaoxindole;
- 23) 3-[(4-phosphonophenyl)methylene]-7-azaoxindole;
- 24) 3-[(4-hydroxyethylpiperazin-1-ylmethyl)phenyl
- 30 methylene]-7-azaoxindole;

WO 96/16964

PCT/EP95/04247

-6-

- 25) 3-[4-(N,N-(4'-hydroxyethyl)piperazinylcarbamoyl)phenyl methylene]-7-azaoxindole;
- 26) 3-[4-sulfophenylmethylen]-7-azaoxindole sodium salt;
- 27) 3-[4-aminophenylmethylen]-7-azaoxindole hydrochloride;
- 5 28) 3-[4-aminophenylmethylen]-7-azaoxindole trifluoroacetate;
- 29) 3-[(3-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)methylene]-7-azaoxindole;
- 10 30) 3-[(1,4-dihydroxy-5,6,7,8-tetrahydronaphth-2-yl)methylene]-7-azaoxindole;
- 31) 3-[(3-(2,3-dihydroxypropoxy)-5,6,7,8-tetrahydronaphth-2-yl)methylene]-7-azaoxindole;
- 32) 3-[(3-methoxy-5,6,7,8-tetrahydronaphth-2-yl)methylene]-7-azaoxindole;
- 15 33) 3-[(4-amino-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;
- 34) 3-[(4-diethanolamino-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;
- 35) 3-[(4-glyceroylamido-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;
- 20 36) 3-[4-(3-piperidinopropionylamino)-5,6,7,8-tetrahydro naphth-1-yl)methylene]-7-azaoxindole;
- 37) 3-[(4-ureido-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;
- 25 38) 3-[(4-mesylamino-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;
- 39) 3-[(4-guanidino-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;
- 40) 3-[(4-sulfo-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;
- 30

WO 96/16964

PCT/EP95/04247

-7-

- 41) 3-[(4-N,N-piperazinylsulfamoyl-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;
- 42) 3-[(4-sulfamoyl-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;
- 5 43) 3-[(4-aminomethyl-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;
- 44) 3-[(4-amidino-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;
- 45) 3-[(4-phosphono-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;
- 10 46) 3-[(4-carboxy-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;
- 47) 3-[(4-carbomethoxy-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;
- 15 48) 3-[(4-quinolyl)methylene]-7-azaoxindole;
- 49) 3-[(8-hydroxy-5-quinolyl)methylene]-7-azaoxindole;
- 50) 3-[(8-sulfo-5-quinolyl)methylene]-7-azaoxindole;
- 51) 3-[(8-sulfamoyl-5-quinolyl)methylene]-7-azaoxindole;
- 52) 3-[(8-aminomethyl-5-quinolyl)methylene]-7-azaoxindole;
- 20 53) 3-[(2-methyl-3-indolyl)methylene]-7-azaoxindole;
- 54) 3-[(3-indolyl)methylene]-7-azaoxindole;
- 55) 3-[(5-hydroxy-3-indolyl)methylene]-7-azaoxindole;
- 56) 3-[(5-methoxy-3-indolyl)methylene]-7-azaoxindole;
- 57) 3-[(5-amino-3-indolyl)methylene]-7-azaoxindole;
- 25 58) 3-[(5-diethanolamino-3-indolyl)methylene]-7-azaoxindole;
- 59) 3-[(5-glycerylamido-3-indolyl)methylene]-7-azaoxindole;
- 60) 3-[(5-(3-piperidinopropionylamino)-3-indolyl)methylene]-7-azaoxindole;
- 30 61) 3-[(5-ureido-3-indolyl)methylene]-7-azaoxindole;

WO 96/16964

PCT/EP95/04247

-8-

62) 3-[(5-mesylamino-3-indolyl)methylene]-7-azaoxindole;
63) 3-[(5-guanidino-3-indolyl)methylene]-7-azaoxindole;
64) 3-[(5-sulfo-3-indolyl)methylene]-7-azaoxindole;
65) 3-[(5-N,N-piperazinylsulfamoyl-3-indolyl)methylene]-7-
5 azaoxindole;
66) 3-[(5-sulfamoyl-3-indolyl)methylene]-7-azaoxindole;
67) 3-[(5-aminomethyl-3-indolyl)methylene]-7-azaoxindole;
68) 3-[(5-amidino-3-indolyl)methylene]-7-azaoxindole;
69) 3-[(5-phosphono-3-indolyl)methylene]-7-azaoxindole;
10 70) 3-[(5-carboxy-3-indolyl)methylene]-7-azaoxindole;
71) 3-[(5-carbomethoxy-3-indolyl)methylene]-7-azaoxindole;
72) 3-[(7-azaindol-3-yl)methylene]-7-azaoxindole;
73) 3-[(4-hydroxy-7-azaindol-3-yl)methylene]-7-azaoxindole;
74) 3-[(4-amino-7-azaindol-3-yl)methylene]-7-azaoxindole;
15 75) 3-[(4-(3-piperidinopropionylamino))-7-azaindol-3-yl)
methylene]-7-azaoxindole;
76) 3-[(4-ureido-7-azaindol-3-yl)methylene]-7-azaoxindole;
77) 3-[(4-sulfo-7-azaindol-3-yl)methylene]-7-azaoxindole;
78) 3-[(4-sulfamoyl-7-azaindol-3-yl)methylene]-7-
20 azaoxindole;
79) 3-[(4-amidino-7-azaindol-3-yl)methylene]-7-azaoxindole;
80) 3-[(4-carboxy-7-azaindol-3-yl)methylene]-7-azaoxindole;
and the pharmaceutically acceptable salts of the above
listed compounds.

25

The compounds of the invention, and the pharmaceutically acceptable salts thereof, can be obtained by a process comprising:


30

a) condensation of an aldehyde of formula (II)


WO 96/16964

PCT/EP95/04247

-9-




wherein A, R₁, R₂ and q are as defined above, with a compound of formula (III)



5 wherein R₃ is as defined above; or

b) N-alkylation of a compound of formula (IV)



wherein A, R₂, R₃ and q are as defined above, thus
 10 obtaining a compound of formula (I), wherein R₁ is
 $-\text{N}(\text{CH}_2\text{CH}_2\text{OH})_2$ or $-\text{NHCH}_2(\text{CHOH})_n\text{CH}_2\text{OH}$ and A, R₂, R₃ and q
 are as defined above; or

c) N-acetylation of a compound of formula (IV), wherein A,
 15 R₂, R₃ and q are as defined above, thus obtaining a
 compound of formula (I) wherein R₁ is $-\text{NHCO}(\text{CHOH})_n\text{CH}_2\text{OH}$

$-\text{NHCO}(\text{CH}_2)_p-\text{N}$
 or and A, R₂, R₃, n, p, q and Z are as
 defined above; or

WO 96/16964

PCT/EP95/04247

-10-

d) N-sulfonylation of a compound of formula (IV) wherein A, R₂, R₃ and q are as defined above, thus obtaining a compound of formula (I) wherein R₁ is -NHSO₂R, and A, R₂, R₃, R₉ and q are as defined above; or

5


e) N-amidination of a compound of formula (IV) wherein A, R₂, R₃ and q are as defined above, thus obtaining a compound of formula (I) wherein R₁ is -NHC(NH₂)=NH and A, R₂, R₃ and q are as defined above; or

10

f) N-carbamoylation of a compound of formula (IV) wherein A, R₂, R₃ and q are as defined above, thus obtaining a compound of formula (I) wherein R₁ is -NHCONH₂ and A, R₂, R₃ and q are as defined above; or

15

g) O-alkylation of a compound of formula (V)



wherein A, R₂, R₃ and q are as defined above, thus obtaining a compound of formula (I) wherein R₁ is

20 -OCH₂(CHOH)_nCH₂OH or -OR₁₀ in which R₁₀ is C₁-C₆ alkyl and A, R₂, R₃ and q are as defined above; or

25 h) O-acylation of a compound of formula (V) wherein A, R₂, R₃ and q are as defined above, thus obtaining a compound of formula (I) wherein R₁ is -OOC(CHOH)_nCH₂OH or -OR₁₀ in which R₁₀ is C₂-C₆ alkanoyl and A, R₂, R₃ and q are as defined above; or

WO 96/16964


PCT/EP95/04247

-11-

i) O-phosphorylation of a compound of formula (V) wherein A, R₂, R₃ and q are as defined above, thus obtaining a compound of formula (I) wherein R₁ is -OPO(OH)₂ and A, R₂, R₃ and q are as defined above; or

5


k) esterification of a compound of formula (VI)



wherein A, R₂, R₃ and q are as defined above, thus obtaining a compound of formula (I) wherein R₁ is -COOR₆ and A, R₂, R₃ and q are as defined above; or


10

l) ammonia addition of a compound of formula (VII)



wherein A, R₂, R₃ and q are as defined above, thus 15 obtaining a compound of formula (I) wherein R₁ is -C(NH₂)=NH and A, R₂, R₃ and q are as defined above; or

m) amination of a compound of formula (VIII)




WO 96/16964

PCT/EP95/04247

-12-

wherein A, R₂, R₃ and q are as defined above, thus obtaining a compound of formula (I) wherein R₁ is -CH₂NH₂,

or  and A, R₂, R₃ and q are as defined above;

5 and/or conversion of a compound of formula (I) into another compound of formula (I) and/or optional saponification of a compound of formula (I) or conversion of a salt into the corresponding free compound of formula (I) and/or, if desired, separation of a mixture 10 of isomers into the single isomers.

The condensation of a compound of formula (II) with a compound of formula (III) according to process step a) may be carried out using known methods, e.g. under the 15 condition of the Knoevenagel reaction as described e.g. by G. Jones in *Organic Reactions* 15, 204 (1967). Suitable catalysts are organic bases such as pyridine, piperidine or diethylamine.

The condensation may be performed in an inert organic 20 solvent e.g. pyridine, ethanol, methanol, benzene or dioxane at temperatures ranging from about 0°C to 100°C. Preferably the reaction is carried out in warm ethanol solution in the presence of piperidine catalyst.

25 The N-alkylation according to process step b) may be carried out according to known methods, e.g. as described in Houben Weyl, "Methoden der Organischen Chemie", Vol. XI/I., page 311 (1957). Thus, in order to obtain compounds of formula (I) wherein R₁ is -N(CH₂CH₂OH)₂, the aromatic


WO 96/16964

PCT/EP95/04247

-13-

amine is reacted with ethylene oxide in water, alcoholic or hydroalcoholic solution at temperatures from e.g. 0°C to 100°C. Preferably the reaction is carried out in hydroalcoholic suspension at about 70-80°C by introducing 5 ethylene oxide gas. On the other hand the N-alkylation according to process step b) in order to obtain compounds of formula (I) wherein R₁ and/or R₂ is -NHCH₂(CHOH)_nCH₂OH can be carried out by reductive amination, i.e. by condensation with an aldehyde of formula CH₂OH(CHOH)_nCHO in 10 the presence of a reducing agent, e.g. as described by Tietze and Eiche in "Reactions and Synthesis in the Organic Chemistry Laboratory" (1988) at page 77. Thus, to the alcoholic solution of the aromatic amine and the aldehyde is added portionwise sodium cyanoborohydride at temperature 15 ranging from 0°C to reflux temperature.

The N-acylation according to process step c) may be carried out by known methods, e.g. as described in Houben-Weyl, Vol. E5, part II, page 960 (1985). Thus, the aromatic amine 20 is reacted with the corresponding carboxylic acid of



formula CH₂OH(CHOH)_nCOOH or , wherein Z, p and n are as defined above by using a condensing agent, such as dicyclohexylcarbodiimide (DCCD). Preferably equimolar amounts of amine, carboxylic acid and 25 dicyclohexylcarbodiimide are used in an inert solvent such as THF or benzene at temperatures from about 0°C to 50°C.

The N-sulfonylation according to process step d) may be carried out by known methods, e.g. as described in Houben-

WO 96/16964

PCT/EP95/04247

-14-

Weyl, Vol. IX, page 609 (1955). Thus, equimolar amounts of aromatic amine and sulphochloride of general formula R⁹-SO₂-Cl are reacted in pyridine solution at temperatures from, e.g. 10°C to 50°C.

5

The N-amidination according to process step e) may be carried out, e.g., as described by P.D. Davis et al. in J. Med. Chem. 1992, 35, 994. Thus, the aromatic amine is treated with about 1.5 molequivalents of 3,5-

10 dimethylpyrazole-1-carboxamidine in refluxing ethanol in the presence of about 1 molequivalents of NaHCO₃.

The N-carbamoylation according to process step f) may be carried out, e.g., as described in Houben-Weyl, Vol. E4, 15 page 362 (1983). Thus the aromatic amine salt, preferably the hydrochloride salt, is reacted with an alkali metal cyanate, preferably NaOCN or KOCN, in aqueous or hydroalcoholic solution at temperature ranging, e.g., from about 50° to about 100°.

20

The O-alkylation according to process step g) may be carried out, e.g., as described in Houben-Weyl, Vol. VI/3, page 54 (1965). Thus the phenol is first transformed into an alkali metal phenolate by treatment with an alkali metal 25 alcoholate or hydroxide or amide. Then the phenolate is reacted with a halogenide of a general formula XCH₂(CHOH)_nCH₂OH (wherein X is chlorine or bromine) in an inert solvent such as benzene or THF at temperature ranging from room to reflux temperature.

WO 96/16964

PCT/EP95/04247

-15-

Preferably the reaction is carried out in benzene solution by reacting the phenol first with a stoichiometric amount of NaNH₂ at room temperature and then with an excess of halogenide at reflux temperature.

5

The O-acylation according to process step h) may be carried out by known methods, e.g., as described in Houben-Weyl, Vol. VIII, page 543 (1952). Thus, the phenol is reacted with the acid halide of general formula CH₂OH(CHOH)_nCOCl in 10 the presence of an organic base such as pyridine or triethylamine at temperatures ranging, e.g., from about 0°C to about 50°C. Alternatively, the phenol is reacted with the acid CH₂OH(CHOH)_nCOOH in the presence of a condensing agent such as dicyclohexylcarbodiimide (DCCD). Preferably 15 equimolar amounts of phenol and DCCD are used and the reaction is conducted in an inert solvent such as THF or benzene at temperatures from about 0°C to about 50°C.

The O-phosphorylation according to process step i) may be 20 carried out by known methods, e.g., as described in Houben-Weyl, Vol. XII/2, page 143 (1962). Thus, the phenol is reacted with the phosphoric acid or a derivative thereof in water or hydroalcoholic solution at temperature ranging from room to reflux temperature. Preferably, the reaction 25 is carried out in polyphosphoric acid (mixture of phosphoric acid and P₂O₅) which acts as reactant and solvent at temperature ranging from about 50°C to about 100°C.

-16-

The esterification according to process step k) may be carried out by well known methods, e.g., as described in Houben-Weyl, Vol. VIII, page 508 (1952). Thus, the mixture of acid and alcohol, dissolved in an inert solvent such as 5 benzene or chloroform, is heated to reflux in the presence of a mineral acid such as H_2SO_4 . Preferably, the water formed is removed by azeotropic distillation in a Dean-Stark condenser.

10 The nitril transformation according to process step l) may be carried out by known methods, e.g. as described in Houben-Weyl, Vol. 8, page 697 and 702 (1952). Thus, to the ether or chloroform solution of the nitril is added an equimolar amount of ethanol and the resulting solution is 15 saturated with HCl gas. The resulting iminoether hydrochloride is then transformed into amidine by reaction with ammonia in absolute ethanol at room temperature.

20 The amination according to process step m) may be carried out by known methods, e.g. as described in Houben-Weyl, Vol. XI/1, page 24 (1957). Thus, a mixture of chloro-methyl compound and piperazine compound is heated to a temperature from, e.g., about 50°C to about 150°C until the reaction is complete.

25


The optional salification of a compound of formula (I) as well as the conversion of a salt into the corresponding free compound and the separation of a mixture of isomers into the single isomers as well as the conversion of a 30 compound of formula (I) into another compound of formula (I) may be carried out according to known methods.

WO 96/16964

PCT/EP95/04247

-17-

For example, the amidation of a compound of formula (I), wherein R₁ is -SO₃H, so as to obtain a compound of formula



(I), wherein R₁ is -SO₂NHR₅ or

 may be carried out by known methods, e.g., as described above at process step 5 d).

The conversion of a compound of formula (I) in which R₁ is -SO₃H into the corresponding compound of formula (I) wherein R₁ is -SO₃R₄ may be carried out by known 10 esterification methods, e.g. as described above at process step k).

The conversion of a compound of formula (I) in which R₁ is -CH₂NH₂ into the corresponding compound of formula (I) 15 wherein R₁ is -CH₂NH-C(NH₂)=NH may be carried out by known amidination methods, e.g. as described above at process step e).

The esterification of a compound of formula (I) wherein R₁ 20 is -CH₂OH in order to obtain a compound of formula (I) wherein R₁ is -CH₂OOC(CH₂OH)_nCH₂OH may be carried out by known amidination methods, e.g. as described above at process step k).


25 The conversion of a compound of formula (I) in which R₁ is -CH₂OH into the corresponding compound of formula (I) wherein R₁ is -CH₂OPO(OH)₂ may be carried out by known amidination methods, e.g. as described above at process step i).

WO 96/16964

PCT/EP95/04247

-18-

The conversion of a compound of formula (I) in which R_1 is $-COOR_6$ and wherein R_6 is preferably methyl into the corresponding compound of formula (I) wherein R_1 is



may be carried out by aminolysis, e.g. as
5 described in Houben-Weyl, vol. E5, page 983 (1985). Preferably a mixture of the carbomethoxy compound and the


amine compound of formula  is heated to reflux and the formed methanol is continuously removed by distillation.

10

The optional salification of a compound of formula (I) as well as the conversion of a salt into the free compound and the separation of a mixture of isomers into the single isomers may be carried out by conventional methods. For 15 example, the separation of a mixture of geometric isomers, e.g. cis- and trans-isomers, may be carried out by fractional crystallization from a suitable solvent or by chromatography, either column chromatography or high pressure liquid chromatography.

20

The compounds of formula (II) may be obtained according to known methods from compounds of formula (IX)



wherein A, R_1 , R_2 and q are as defined above.

25

WO 96/16964

PCT/EP95/04247

-19-

For example the 3-formylindole derivative of formula (II) can be obtained from an indole derivative of formula (IX) wherein A is indole and R₁, R₂ and q are as defined above, by formylation with N-methylformanilide and phosphorous oxychloride according to the well known Vilsmeye-Haak method (for a review see W.G. Jackson et al. in J. Am. Chem. Soc. 1981, 103, 533). The 2-formyl-indole derivatives are obtained when the 3-position is occupied.

10 The 3-formyl-7-azaindole derivatives of formula (II) wherein A is 7-azaoxindole and R₁, R₂ and q are as defined above may be obtained by using the Vilsmeye-Haak method as described above.

15 Moreover, phenolic compounds of formula (II) wherein A is benzene, naphthalene or 5,6,7,8-tetrahydronaphthalene may be obtained from the corresponding phenolic compounds of formula (IX) according to the well known method of Reimer-Tiemann by reaction with chloroform and alkali hydroxides

20 in an aqueous or hydroalcoholic solution.

The compounds of formula (III) are known or may be obtained by known methods from known compounds. E.g. according to Marfat and Carta (Tetrahedron Letters, 1987, 28, 4027) the parent compound is obtained by brominating indole with pyridinium bromide perbromide to give 3,3-dibromo-7-azaoxindole which is then reduced to 7-azaoxindole with zinc in acetic acid.

30 A compound of formula (IV), (V), (VI), (VII) or (VIII) that is a compound of formula (I) wherein R₁ is, respectively,

WO 96/16964

PCT/EP95/04247

-20-

-NH₂, -OH, -COOH, -CN or -CH₂Cl, may be obtained by condensation of a compound of formula (II) wherein R₁ is -NH₂, -OH, -COOH, -CN or -CH₂Cl respectively, and R₂ and A are as defined above, with a compound of formula (III) 5 according to process step a).

When in the new compounds of the present invention and in the intermediate products used for their preparation groups are present which need to be protected before submitting 10 them to the hereabove illustrated reactions, they may be protected before the reaction takes place and then deprotected at the end of the reaction, according to well known methods in organic chemistry.

15 The compounds of the invention possess specific tyrosine kinase inhibiting activity. It is believed that tyrosine kinase inhibitors may be of great importance in the control of uncontrolled cellular reproduction, i.e. in cellular reproduction disorders. Hence, the compounds according to 20 the present invention can be useful in the treatment of pathological proliferation disorders in mammals, including humans. Typical examples of such disorders are tumors, including leukemia, and psoriasis. The compounds of the invention can also be useful in inhibiting the development 25 of the atheromatous plaque and in the control of angiogenesis and as anti-metastatic agents.

Recent studies on the molecular basis of the neoplastic transformation have identified a family of genes, designed oncogenes, whose aberrant expression causes tumorigenesis.

30 For example, the RNA tumor viruses possess such an oncogene sequence whose expression determines neoplastic conversion

WO 96/16964

PCT/EP95/04247

-21-

of infected cells. Several of their oncogene-encoded proteins, such as pp60^{v-src}, p70^{gag-yes}, p130^{gag-fps} and p70^{gag-fgr} display protein tyrosine kinase activity, that is they catalyze the transfer of the gamma-phosphate from adenosine 5 triphosphate (ATP) to tyrosine residues in protein substrate. In normal cells, several growth factor receptors, for example the receptors for PDGF, EGF, α -TGF and insulin, display tyrosine kinase activity.

Binding of the growth factor (GF) activates the receptors 10 tyrosine kinase to undergo autophosphorylation and to phosphorylate closely adjacent molecules on tyrosine. Therefore, it is thought that the phosphorylation of these tyrosine kinase receptors plays an important role in signal transduction and that the principal function of tyrosine 15 kinase activity in normal cells is to regulate cell growth. Perturbation of this activity by oncogenic tyrosine kinases that are either overproduced and/or display altered substrate specificity may cause loss of growth control and/or neoplastic transformation. Accordingly, a specific 20 inhibitor of tyrosine kinase can be useful in investigating the mechanism of cancerogenesis, cell proliferation and differentiations and it can be effective in the prevention and chemotherapy of cancer and in other pathological proliferative conditions, for instance as mentioned above.

25

The tyrosine specific protein kinase activity of the compounds of the invention is shown, e.g., by the fact that they are active in the in-vitro and in-vivo test described herebelow.

30

-22-

In-Vitro Assay

p45 v-abl Kinase Purification

The enzyme used in our tests was the p45 v-abl tyrosine kinase which represents the catalytic domain of the Abelson tyrosine kinase (isolated from the Abelson murine leukemia virus). The p45 v-abl kinase was produced and isolated as described by Wang et al. in J. Biol. Chem. 260, 64 (1985) and by Ferguson et al. in J. Biol. Chem. 260, 3652 (1985) and in Biochem. J. 257, 321 (1989).

10

p45 v-abl Kinase Assay

(Val⁵)-Angiotensin II phosphorylation was performed by incubation with 40 ng of purified abl-kinase and (γ^{32} -p)-ATP, in 50 μ l of buffer containing Tris-HCl 25 mM, pH 8.0. 15 MgCl₂ 10 mM and dithiothreitol 0.1 mM (kinase buffer). The reaction mixture was incubated for the indicated time at 30°C and the reaction stopped by adding 50 μ l of 5% trichloroacetic acid. After a brief incubation on ice, tubes were centrifuged. The supernatants were spotted on 20 phosphocellulose paper squares (Whatman P-81) and washed extensively in acetic acid. The radioactivity bound to dried phosphocellulose squares was measured in a liquid scintillation counter. IC₅₀ values were calculated from triplicated determinations of each experimental point. Each 25 inhibitor was tested at concentrations ranging from 0 to 400 μ g in the presence of fixed concentrations of peptide (2 mM) and ATP (50 μ M).

30

-23-

In-Vivo AssayK562 Cell Growth Inhibition Assay

K562 cells, a human myelogenous leukemia cell line, were seeded into a 24 wells tissue culture plate (Falcon 3047) 5 (10000/well) in the presence of increasing concentrations of the compounds. After 72 h, cells were harvested and were counted using a cell counter (Coulter Counter - ZM). The percent of inhibition was evaluated in respect to the untreated control cells.

10

The inhibitory activity data for a representative group of compounds according to the present invention, obtained both in the in-vitro p45 v-abl kinase assay and in the in vivo human chronic myeloid leukemia K562 cell growth inhibition 15 assay described above, are set out in the following Table I.

Table I

Compound	IC ₅₀ (μM)	
	v-abl	K562
3-[(7-azaindol-3-yl)methylene]- 7-azaoxindole	1.04	3.89
3-[(1,4-dihydroxy-5,6,7,8- tetrahydronaphth-2-yl)methylene]- 7-azaoxindole	2.14	2.36
3-[(5-methoxy-3-indolyl)methylene]- 7-azaoxindole	0.03	3.21
3-[(2-methyl-3-indolyl)methylene]- 7-azaoxindole	0.04	2.61

WO 96/16964

PCT/EP95/04247

-24-

In view of their high activity and low toxicity, the compounds of the invention can be used safely in medicine.

For example, the approximate acute toxicity (LD_{50}) of the compounds of the invention in the mouse, determined by

5 single administration of increasing doses and measured on the seventh day after the treatment was found to be negligible.

The compounds of the invention can be administered in a

10 variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar or film-coated tablets, liquid solutions or suspensions; rectally, in the form of suppositories; parenterally, e.g. intramuscularly, or by intravenous injection or infusion; or topically. The dosage

15 depends on the age, weight, condition of the patient and administration route; for example, the dosage adopted for oral administration to adult humans may range from about 10 to about 150-200 mg per dose, from 1 to 5 times daily. Of course, these dosage regimens may be adjusted to provide

20 the optimal therapeutic response.

The invention includes pharmaceutical compositions comprising a compound of formula (I) or pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient (which can be a carrier or diluent).

The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.

30 For example, the solid oral form may contain, together with the active compound, diluents, e.g., lactose, dextrose,

WO 96/16964

PCT/EP95/04247

-25-

saccharose, cellulose, corn starch or potato starch; lubricant, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums, gelatin,

5 methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. a starch, alginic acid, alginates or sodium starch glycolate, effervesing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general,

10 non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating or film-coating processes.

15 The liquid dispersion for oral administration may be e.g. syrups, emulsions and suspensions. The syrup may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

20 The suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose or polyvinyl alcohol.

The suspensions or solutions for intramuscular injections

25 may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol and, if desired, a suitable amount of lidocaine hydrochloride.

30 The solutions for intravenous injections or infusion may contain as carrier, for example, sterile water or,

WO 96/16964

PCT/EP95/04247

-26-

preferable, they may be in the form of sterile aqueous, isotonic saline solutions.

The suppositories may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g.

5 cocoa-butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
Compositions for topical application, e.g. creams, lotions, or pastes, can be prepared by admixing the active
ingredient with a conventional oleaginous or emulsifying
10 excipient.

A further object of the present invention is a combined method of treatment of cancer in mammals, including humans, in need of such treatment, said method comprising administering:

15 1) a compound of formula (I), or a pharmaceutically acceptable salt thereof, and
2) an additional antitumor agent, in amounts and close enough together in time sufficient to produce a therapeutically useful effect.
20 Object of the present invention is also to provide products containing a compound of formula (I), or a pharmaceutically acceptable salt, and an additional antitumor agent as a combined preparation for simultaneous, separate or sequential use in anti-cancer therapy.
25 The term "antitumor agent" is meant to comprise both a single antitumor drug and "cocktails" i.e. a mixture of such drugs, according to the clinical practice.
Antitumor agents that can be formulated with a compound of the invention or alternatively, can be administered in a
30 combined method of treatment, can be, e.g., doxorubicin, daunomycin, epirubicin, idarubicin, etoposide,

WO 96/16964

PCT/EP95/04247

-27-

fluorouracil, melphalan, cyclophosphamide, bleomycin, vinblastine and mitomycin or a mixture of two or more thereof.

The compounds of the invention can therefore be used in a 5 treatment to ameliorate a cancer. They may be administered to a patient suffering from a cancer treatable with an antitumor agent, for example and anthracycline glycoside such as doxorubicin, daunomycin, epirubicin or idarubicin as mentioned above, together with the antitumor agent. 10 A compound of the invention and an antitumor agent such e.g. as an anthracycline glycoside can be administered to improve the condition of a patient having a leukemia such as myeloblastic leukaemia, lymphoma, sarcoma, neuroblastoma, Wilm's tumor or malignant neoplasm of the 15 bladder, breast, lung or thyroid.

The following examples illustrate but do not limit the invention:

20 Example 1

3-[(3,5-di-t-butyl-4-hydroxyphenyl)methylene]7-azaoindole

A solution of 3,5-di-t-butyl-4-hydroxybenzaldehyde (2.343g, 10 mmol), 7-azaoindole (1.341g, 10 mmol) and piperidine 25 (0.255g, 3 mmol) in absolute ethanol (50 ml) has heated for 3 h at reflux. The reaction mixture was chilled to 5-10°C, the precipitate filtered, the residue washed with ice-cold ethanol and dried under vacuum. Almost pure title compound was so obtained in about 80% yield (0.280g). 30 Compound of higher purity were obtained by crystallization from ethanol.

WO 96/16964

PCT/EP95/04247

-28-

$C_{22}H_{26}N_2O_2$ calcd: C 75.40 H 7.50 N 7.99
 found: C 75.35 H 7.52 N 7.85

MS m/z 350

NMR E-isomer (DMSO) δ 1.40 (s, 3H), 6.9-7.0 (m, 1H), 7.52 (s, 1H), 7.70 (s, 1H), 7.71 (bs, 1H), 7.93 (dd, J=1.7 and 8.5 Hz, 1H), 8.07 (dd, J=1.7 and 5.1 Hz, 1H), 11.12 (s, 1H)

According to the above described procedure and starting from the appropriate compound of formula (II) and of 10 formula (III), one can prepare the following compounds as single E- or Z-isomers, as well as their E,Z-mixtures:

3-[(1,4-dihydroxy-5,6,7,8-tetrahydronaphth-2-yl)methylene]-7-azaoxindole;

15 $C_{18}H_{16}N_2O_3$ calcd: C 70.12 H 5.23 N 9.08
 found: C 70.05 H 5.15 N 9.01

MS m/z 308

NMR E-isomer (DMSO) δ 1.67 (m, 4H), 6.91 (s, 1H), 6.92 (dd, J=5.1 and 7.6 Hz, 1H), 7.84 (s, 1H), 7.91 (dd, J=7.6 and 20 1.5 Hz, 1H), 8.06 (dd, J=5.1 and 1.5 Hz, 1H), 8.4 (bs, 3H), 9.01 (s, 1H), 11.10 (s, 1H)

3-[(3-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)methylene]-7-azaoxindole;

25 $C_{18}H_{16}N_2O_2$ calcd: C 73.95 H 5.52 N 9.58
 found: C 73.66 H 5.55 N 9.45

MS m/z 292

3-[(4-quinolyl)methylene]-7-azaoxindole;

30 $C_{17}H_{14}N_2O$ calcd: C 74.71 H 4.06 N 15.38
 found: C 71.65 H 3.95 N 15.42

WO 96/16964

PCT/EP95/04247

-29-

MS m/z 273

3-[(2-methyl-3-indolyl)methylene]-7-azaoxindole;

C₁₇H₁₃N₃O calcd: C 74.17 H 4.76 N 15.26

5 found: C 74.15 H 4.66 N 15.30

MS m/z 275

NMR Z-isomer (DMSO) δ 6.79 (dd, J=7.5 and 5.0 Hz, 1H), 6.86 (dd, J=7.5 and 1.8 Hz, 1H), 6.9-7.5 (m, 4H), 7.94 (s, 1H), 7.99 (dd, J=1.8 and 5.0 Hz, 1H), 11.0 (bs, 1H), 12.0 (bs, 10 1H)

3-[(3-indolyl)methylene]-7-azaoxindole;

C₁₆H₁₁N₃O calcd: C 73.55 H 4.24 N 16.08

found: C 73.48 H 4.19 N 15.55

15 MS m/z 261

NMR Z-isomer (DMSO) δ 7.00 (dd, J=5.2 and 7.4 Hz, 1H), 7.24 (m, 2H), 7.52 (m, 1H), 8.01 (dd, J=5.2 and 1.4 Hz, 1H), 8.1-8.3 (m, 3H), 9.43 (bs, 1H), 11.1 (bs, 1H), 12.1 (bs, 1H)

20

3-[(5-methoxy-3-indolyl)methylene]-7-azaoxindole;

C₁₇H₁₃N₃O₂ calcd: C 70.09 H 4.50 N 14.42

found: C 70.01 H 4.45 N 14.35

MS m/z 291

25 NMR Z-isomer (DMSO) δ 3.86 (s, 3H), 6.86 (dd, J=2.4 and 8.7 Hz, 1H), 6.99 (dd, J=5.1 and 7.6 Hz, 1H), 7.40 (d, J=8.7 Hz, 1H), 7.71 (d, J=2.4 Hz, 1H), 8.00 (dd, J=5.1 and 1.5 Hz, 1H), 8.19 (dd, J=7.6 and 1.5 Hz, 1H), 8.21 (s, 1H), 9.32 (s, 1H), 11.0 (bs, 1H), 12.0 (s, 1H).

30

3-[(7-azaindol-3-yl)methylene]-7-azaoxindole;

WO 96/16964

PCT/EP95/04247

-30-

 $C_{15}H_{10}N_4O$ calcd: C 68.69 H 3.84 N 21.36

found: C 68.65 H 3.85 N 21.25

MS m/z 262

NMR Z-isomer (DMSO) δ 7.02 (dd, J=5.3 and 7.5 Hz, 1H), 7.29

5 (dd, J=4.5 and 7.9 Hz, 1H), 8.03 (dd, J=5.3 and 1.5 Hz, 1H), 8.16 (dd, J=7.5 and 1.5 Hz, 1H), 8.22 (s, 1H), 8.35 (dd, J=4.5 and 1.5 Hz, 1H), 8.58 (dd, J=7.9 and 1.5 Hz, 1H), 9.49 (s, 1H), 11.14 (s, 1H), 12.6 (bs, 1H).

10 3-[(4-hydroxyphenyl)methylene]-7-azaoxindole;
3-[(4-(2,3-dihydroxypropoxy)phenylmethylene]-7-azaoxindole;
3-[(4-methoxyphenyl)methylene]-7-azaoxindole;
3-[(4-aminophenyl)methylene]-7-azaoxindole;
3-[(4-diethanolaminophenyl)methylene]-7-azaoxindole;
15 3-[(4-glycerylaminophenyl)methylene]-7-azaoxindole;
3-[(4-(3-piperidinopropionylamino)phenyl)methylene]-7-
azaoxindole;
3-[(4-ureidophenyl)methylene]-7-azaoxindole;
3-[(4-mesylaminophenyl)methylene]-7-azaoxindole;
20 3-[(4-guanidinophenyl)methylene]-7-azaoxindole;
3-[(4-sulfophenyl)methylene]-7-azaoxindole;
3-[(4-N,N-piperazinylsulfamoylphenyl)methylene]-7-
azaoxindole;
3-[(4-sulfamoylphenyl)methylene]-7-azaoxindole;
25 3-[(4-aminomethylphenyl)methylene]-7-azaoxindole;
3-[(4-amidinophenyl)methylene]-7-azaoxindole;
3-[(4-phosphonoxyphenyl)methylene]-7-azaoxindole;
3-[(4-carboxyphenyl)methylene]-7-azaoxindole;
3-[(4-carbomethoxyphenyl)methylene]-7-azaoxindole;
30 3-[(4-hydroxymethylphenyl)methylene]-7-azaoxindole;

WO 96/16964

PCT/EP95/04247

-31-

3-[4-(2,3-dihydroxypropylamino)phenylmethylene]-7-azaoxindole;

3-[4-glycoloyloxyphenyl)methylene]-7-azaoxindole;

3-[4-phosphonophenyl)methylene]-7-azaoxindole;

5 3-[4-hydroxyethyl-1-piperazin-1-ylmethyl)phenylmethylene]-7-azaoxindole;

3-[4-(N,N-(4'-hydroxyethyl)piperazinylcarbamoyl)phenylmethylene]-7-azaoxindole;

3-[4-sulfophenylmethylene]-7-azaoxindole sodium salt;

10 3-[4-aminophenylmethylene]-7-azaoxindole hydrochloride;

3-[4-aminophenylmethylene]-7-azaoxindole trifluoroacetate;

3-[3-(2,3-dihydroxypropoxy)-5,6,7,8-tetrahydronaphth-2-yl)methylene]-7-azaoxindole;

3-[3-methoxy-5,6,7,8-tetrahydronaphth-2-yl)methylene]-7-azaoxindole;

15 3-[4-amino-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;

3-[4-diethylamino-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;

3-[4-glycerylamino-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;

20 3-[4-(3-piperidinopropionylamino)-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;

3-[4-ureido-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;

25 3-[4-mesylamino-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;

3-[4-guanidino-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;

30 3-[4-sulfo-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;

WO 96/16964

PCT/EP95/04247

-32-

3-[(4-N,N-piperazinylsulfamoyl-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;

3-[(4-sulfamoyl-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;

5 3-[(4-aminomethyl-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;

3-[(4-amidino-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;

10 3-[(4-phosphono-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;

3-[(4-carboxy-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;

3-[(4-carbomethoxy-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-azaoxindole;

15 3-[(8-hydroxy-5-quinolyl)methylene]-7-azaoxindole;

3-[(8-sulfo-5-quinolyl)methylene]-7-azaoxindole;

3-[(8-sulfamoyl-5-quinolyl)methylene]-7-azaoxindole;

3-[(8-aminomethyl-5-quinolyl)methylene]-7-azaoxindole;

3-[(5-hydroxy-3-indolyl)methylene]-7-azaoxindole;

20 3-[(5-amino-3-indolyl)methylene]-7-azaoxindole;

3-[(5-diethanolamino-3-indolyl)methylene]-7-azaoxindole;

3-[(5-glycerylamido-3-indolyl)methylene]-7-azaoxindole;

3-[(5-(3-piperidinopropionylamino)-3-indolyl)methylene]-7-azaoxindole;

25 3-[(5-ureido-3-indolyl)methylene]-7-azaoxindole;

3-[(5-mesylamino-3-indolyl)methylene]-7-azaoxindole;

3-[(5-guanidino-3-indolyl)methylene]-7-azaoxindole;

3-[(5-sulfo-3-indolyl)methylene]-7-azaoxindole;

3-[(5-N,N-piperazinylsulfamoyl-3-indolyl)methylene]-7-

30 azaoxindole;

3-[(5-sulfamoyl-3-indolyl)methylene]-7-azaoxindole;

WO 96/16964

PCT/EP95/04247

-33-

3-[(5-aminomethyl-3-indolyl)methylene]-7-azaoxindole;
3-[(5-amidino-3-indolyl)methylene]-7-azaoxindole;
3-[(5-phosphono-3-indolyl)methylene]-7-azaoxindole;
3-[(5-carboxy-3-indolyl)methylene]-7-azaoxindole;
5 3-[(5-carbomethoxy-3-indolyl)methylene]-7-azaoxindole;
3-[(7-azaindol-3-yl)methylene]-7-azaoxindole;
3-[(4-hydroxy-7-azaindol-3-yl)methylene]-7-azaoxindole;
3-[(4-amino-7-azaindol-3-yl)methylene]-7-azaoxindole;
3-[(4-(3-piperidinopropionylamino))-7-azaindol-3-yl)
10 methylene]-7-azaoxindole;
3-[(4-ureido-7-azaindol-3-yl)methylene]-7-azaoxindole;
3-[(4-sulfo-7-azaindol-3-yl)methylene]-7-azaoxindole;
3-[(4-sulfamoyl-7-azaindol-3-yl)methylene]-7-azaoxindole;
3-[(4-amidino-7-azaindol-3-yl)methylene]-7-azaoxindole;
15 3-[(4-carboxy-7-azaindol-3-yl)methylene]-7-azaoxindole.

Example 2

3-[4-(2,3-dihydroxypropylamino)phenylmethylene]-7-
azaoxindole
20 To a stirred solution of 3-(4-aminobenzylidene)-7-azaindole
(2.373g, 10 mmol) in methanol (30 ml) was added anhydrous
methylammonium chloride (0.60 g, 10 mmol). Then sodium
cyanoborohydride (0.378 g, 6 mmol) was added in portions.
25 Finally, glyceraldehyde (0.901 g, 10 mmol) was added
portionwise over 30 min and the solution stirred at room
temperature for 50 h. Ice cold 6N HCl was added until gas
evolution (HCN) stopped and the pH of the solution was 2.
The methanol was evaporated in vacuo and the remaining
30 aqueous solution was washed with CHCl₃. Solid KOH was added
until the pH was 12. Solid NaCl was added to saturation and

WO 96/16964

PCT/EP95/04247

-34-

the solution extracted twice with CHCl₃. The CHCl₃ extracts were washed with saturated NaCl solution, dried over K₂CO₃ and evaporated. The residue was chromatographed on silica gel using CHCl₃-MeOH mixtures as eluant. Thus pure title 5 compound was obtained in about 60% yield.

C₁₇H₁₇N₃O₃ calcd: C 65.58 H 5.51 N 13.50
 found: C 65.57 H 5.45 N 13.55

MS m/z 311

10 Example 3

3-[(4-glyceroylamidophenyl)methylene]-7-azaoxindole

To a stirred solution of 3-(4-aminobenzylidene)-7-azaoxindole (2.373 g, 10 mmol) and glyceric acid (1.061 g, 15 10 mmol) in benzene (200 ml) was added dicyclohexyl carbodiimide (2.063 g, 10 mmol). The resulting suspension was stirred for 1 h at 50 - 60°C and then for 3 days at room temperature. Then the N,N'-dicyclohexylurea was filtered off, the filtrate evaporated and the residue 20 chromatographed on silica gel using CHCl₃-MeOH mixtures as eluant. Thus pure title compound was obtained in about 50% yield.

C₁₇H₁₅N₃O₄ calcd: C 62.76 H 4.65 N 12.92
 found: C 62.65 H 4.63 N 12.85

25 MS m/z 325

IR cm⁻¹: 3600-2500 (NH, OH), 1680 (CO), 1650 (CO), 1620 (amide)

Example 4

30 3-[(4-mesylaminophenyl)methylene]-7-azaoxindole

WO 96/16964

PCT/EP95/04247

-35-

To a stirred solution of 3-(4-aminobenzylidene)-7-azaoxindole (2.373 g, 10 mmol) in pyridine (10 ml) was added gradually mesylchloride (1.146 g, 10 mmol) at 0-5°C under cooling. The reaction mixture was stirred for about 5

5 h at 0-5°C and then for 15 h at room temperature.

The mixture was poured onto an ice-water mixture, the precipitate filtered off, the residue washed thoroughly with water and then chromatographed on silica gel using CHCl₃-MeOH mixtures as eluant. Thus pure title compound was

10 obtained in about 70% yield.

C₁₅H₁₃N₃O₃S calcd: C 57.13 H 4.15 N 13.32 S 10.17

found: C 57.05 H 4.08 N 13.25 S 10.05

MS m/z 315

IR cm⁻¹: 3600-3000 (NH), 1650 (CO), 1600, 1580 (C=C).

15

Example 5

3-[(4-guanidinophenyl)methylene]-7-azaoxindole

A mixture of 3-(4-aminobenzylidene)-7-azaoxyindole (2.373

20 g, 10 mmol) and sodium bicarbonate (0.168 g, 2 mmol) in refluxing ethanol (100 ml) was treated with 3,5-

dimethylpyrazole-1-carboxamidine nitrate (3.018 g, 15 mmol)

for 20 h. The solvent was removed from the cooled solution, and the residue was chromatographed on silica gel with

25 gradient elution (1 to 5% EtOH in CHCl₃) to afford pure title compound in about 50% yield.

C₁₇H₁₄N₅O calcd: C 64.57 H 4.69 N 25.07

found: C 64.45 H 4.55 N 29.95

MS m/z 279

30 IR cm⁻¹: 3600-3100 (NH), 1680 (C=NH), 1655 (CONH), 1620, 1580 (C=C).

WO 96/16964

PCT/EP95/04247

-36-

Example 6

3-[(4-ureidophenyl)methylene]-7-azaoxindole

A mixture of 3-(4-aminobenzylidene)-7-azaoxindole (2.373 g, 5 10 mmol) in ice water (20 ml) are added 5N HCl (2 ml, 10 mmol) under stirring. Then the mixture was heated to 70-80°C, sodium cyanate (0.715 g, 11 mmol) was added portionwise and the stirring was continued for further 4 h at this temperature.

10 After cooling the raw product was extracted with CHCl₃, the organic layer washed to neutrality with saline solution, dried and evaporated in vacuo.

The residue was chromatographed on silica gel using CHCl₃-MeOH mixtures as eluant to give pure title compound in 15 about 50% yield.

C₁₅H₁₂N₄O₂ calcd: C 64.28 H 4.32 N 19.99
 found: C 64.30 H 4.25 N 19.81

MS m/z 280

IR cm⁻¹: 3600-3000 (NH), 1660 (CO), 1645 (CO), 1610, 1590
20 (C=C)

Example 7

3-[(4-(2,3-dihydroxypropoxyphenoxy)methylene]-7-azaoxindole

25 To a solution of 3-(4-hydroxybenzylidene)-7-azaoxindole (2.383 g, 10 mmol) in toluene (100 ml) was added portionwise under nitrogen NaH 80% (0.300 g, 10 mmol). After the salification was complete 3-chloro-1,2-propane-diol (1.547 g, 14 mmol) was added and the mixture heated to 30 reflux for 5 h.

WO 96/16964

PCT/EP95/04247

-37-

After cooling water was added, the organic phase washed and evaporated to dryness. The residue was submitted to flash chromatography using CHCl₃-MeOH mixtures as eluant to give pure title compound in about 70% yield.

5 C₁₇H₁₆N₂O₄ calcd: C 65.38 H 5.16 N 8.99
 found: C 65.25 H 5.05 N 8.85

MS m/z 312

IR cm⁻¹: 3600-2600 (NH, OH), 1660 (CO), 1610, 1580, (C=C).

10 Example 8

3-[(4-glycoloyloxyphenyl)methylene]-7-azaoxindole

To a stirred solution of 3-(4-hydroxybenzylidene)-7-azaoxindole (2,383 g. 10 mmol) in pyridine (10 ml) was 15 added gradually glycoloyl chloride (0.945 g, 10 mmol) at 0-5°C under cooling. The reaction mixture was stirred for about 4 h at 0-5°C and then for 15 h at room temperature. The mixture was poured onto an ice-water mixture, the precipitate filtered off, the residue washed thoroughly 20. with water and then chromatographed on silica gel using CHCl₃-MeOH mixtures as eluant. Thus pure title compound was obtained in about 60% yield.

C₁₆H₁₂N₂O₄ calcd: C 64.86 H 4.08 N 9.45
 found: C 64.81 H 3.98 N 9.25

25 MS m/z 296

IR cm⁻¹: 3600-2600 (NH, OH), 1740 (CO), 1660 (CO), 1620, 1580.

Example 9

30 3-[(4-phosphonoxyphenyl)methylene]-7-azaoxindole

WO 96/16964

PCT/EP95/04247

-38-

A mixture of 3-(4-hydroxybenzylidene)methylene]-7-azaoxindole (2.383 g, 10 mmol) and phosphoric acid 85 % (13 g) and phosphorus pentoxide (10 g) was heated for 2 h at 60°C. The usual work up gave the title compound in about 50 % yield.

C₁₄H₁₁N₂C₅P calcd: C 52.84 H 3.48 N 8.80 P 9.73
 found: C 52.79 H 3.45 N 8.75 P 9.65

MS m/z 318

10 Example 10

3-[(4-carbomethoxyphenyl)methylene]-7-azaoxindole

A solution of 3-(4-carboxybenzylidene)-7-azaoxindole (2.663 g, 10 mmol), methanol (3.2 g, 0.1 mol) and H₂SO₄ 95 % (1 g) in benzene (100 ml) was heated in a Soxhlet apparatus for 10 h. To dry the distillate continuously, the cap of the Soxhlet contained anhydrous MgSO₄. After cooling, water was added, the organic phase repeatedly washed with water and then evaporated under vacuum. Thus almost pure title compound was obtained in about 90% yield.

C₁₅H₁₂N₂O₃ calcd: C 67.16 H 4.51 N 10.44
 found: C 67.05 H 4.45 N 13.35

MS m/z 268

IR cm⁻¹: 3600-3200 (NH), 1720 (COOMe), 1660 (CO), 1620, 1600, 1580.

Example 11

3-[(4-amidinophenyl)methylene]-7-azaoxindole hydrochloride

30 To a solution of 3-(4-cyanobenzylidene)-7-azaoxindole (2.473 g, 10 mmol) in anhydrous diethylether (100 ml) a

-39-

stoichiometric amount of ethanol (0.460 g, 10 mmol) was added and the solution was saturated with hydrogen chloride gas. The solution was kept overnight in the fridge in order to precipitate the iminoether hydrochloride salt.

5 The precipitated aminoether hydrochloride was dissolved in ethanol (50 ml) to which was added an anhydrous alcoholic ammonia solution. Thereupon the solution was kept several days at room temperature and the precipitated little amount of NH₄Cl was filtered off. The solution was evaporated in
10 vacuum, thus obtaining almost pure title compound.

C₁₅H₁₂N₄O.HCl calcd: C 59.91 H 4.36 N 18.63 Cl 11.79
found: C 59.85 H 4.25 N 18.55 Cl 11.80

MS m/z 300

15 Example 12

3-(4-hydroxyethyl-1-piperazinylmethyl)phenylmethylen]-7-azaoxindole

A mixture of 3-(4-chloromethylbenzylidene)-7-azaoxindole
20 (2.707 g, 10 mmol) and 4-hydroxyethylpiperazine (2.604 g, 20 mmol) in 1N NaOH (20 ml, 20 mmol) was refluxed for 48 h. The cooled reaction mixture was extracted with ether, and the ether extract was shaken with diluted hydrochloric acid. The aqueous acid layer was made alkaline with
25 potassium carbonate and extracted with ether. Addition of hydrogen chloride to the dried ether extract precipitated a crude hydrochloride which was crystallized twice from a mixture of methanol and ether.

C₂₁H₂₄N₄O₂HCl calcd: C 62.91 H 6.29 N 13.98 Cl 8.84
30 found: C 62.85 H 6.15 N 13.85 Cl 8.75

MS m/z 400

WO 96/16964

PCT/EP95/04247

-40-

Example 13

3-[4-[N,N-(4-hydroxyethyl)piperazinylcarbamoyl]phenyl
methylene]-7-azaoxindole

5 A mixture of 3-(4-carbomethoxybenzylidene)-7-azaoxindole (2.803 g, 10 mmol), 4-hydroxyethyl-piperazine (1.302 g, 10 mmol) and sodium methoxide (0.540 g, 10 mmol) in benzene (50 ml) was heated to reflux for 10h. After cooling water was added cautiously, the organic phase was washed
10 thoroughly with water and then evaporated under vacuum. The residue was submitted to column chromatography on silica gel using CHCl₃-MeOH mixtures as eluant. Thus pure title compound was obtained in about 60% yield.

C₂₁H₂₂N₄O₃ calcd: C 66.65 H 5.86 N 14.81

15 found: C 66.55 H 5.75 N 14.57

MS m/z 378

Example 14

3-[4-sulfophenylmethylene]-7-azaoxindole sodium salt

20 To a solution of 3-(4-sulfonylbenzylidene)-7-azaoxindole (3.206 g, 10 mmol) in 1N NaOH (10 ml, 10 mmol) was added isopropanol (30 ml) and the mixture was chilled under stirring to 0-5°C. The precipitated sodium salt was
25 filtered, washed with ice-cooled isopropanol and dried under vacuum.

C₁₄H₉N₂O₄SNa calcd: C 51.85 H 2.80 N 8.64 S 9.89 Na 7.09

found: C 51.75 H 2.75 N 8.60 S 9.81 Na 6.95

MS m/z 324

30

WO 96/16964

PCT/EP95/04247

-41-

Example 15

3-(4-aminophenylmethylene)-7-azaoxindole hydrochloride salt

To a solution of 3-(4-aminobenzylidene)-7-azaoxindole (2.373
5 g, 10 mmol) in ethanol (10 ml) was added 1N hydrochloridric
acid (2 ml, 2 mmol) and the resulting mixture was
evaporated to dryness under vacuum thus giving pure title
compound in about 100% yield.

10 $C_{14}H_{11}N_3O \cdot HCl$ calcd: C 61.43 H 4.42 N 15.35 Cl 12.95
found: C 61.35 H 4.39 N 15.31 Cl 12.81

MS m/z 273

Example 16

15 3-(4-aminophenylmethylene)-7-azaoxyindole trifluoroacetate
salt

To a solution of 3-(4-aminobenzylidene)-7-azaoxindole
(0.237 g, 1 mmol) in ethanol (10 ml) was added
trifluoroacetic acid (0.114g, 1 mmol) and the solution was
20 concentrated under vacuum to a small volume. Ether was
added to precipitate the salt, the mixture was ice-cooled,
the solid was filtered off, washed with cold ether and
essicated under vacuum. Thus almost pure title compound was
obtained in about 90% yield.

25 $C_{16}H_{12}F_3N_3O_3$ calcd: C 54.71 H 3.44 N 11.96 F 16.23
found: C 54.65 H 3.35 N 11.85 F 16.25

MS m/z 351

Example 17

30 7-azaindol-3-carboxaledehyde

WO 96/16964

PCT/EP95/04247

-42-

A solution of 7-azaindole (23.6 g, 0.20 mol) and hexamethylenetetramine (42 g, 0.30 mol) in 33% acetic acid (84 g, 1.4 mol and 168 ml H₂O) was refluxed for 6 h. The resulting clear yellow solution was diluted with water, and the product was allowed to crystallize in the refrigerator overnight. Recrystallization of the crude product from water gave almost pure title compound in 50% yield (14.9 g).

m.p. 216-218°C

10 C₈H₆N₂O calcd: C 65.74 H 4.13 N 19.17
 found: C 65.65 H 4.25 N 19.25

MS m/z 146

Example 18

15 Tablets each weighing 0.150 g and containing 25 mg of the active substance, can be manufactured as follows:
Composition (for 10,000 tablets):

3-[(3,5-di-*t*-butyl-4-hydroxyphenyl)]

20	methylen]-7-azaoxindole	250 g
	Lactose	800 g
	Corn starch	415 g
	Talc powder	30 g
	Magnesium stearate	5 g
25	-----	

The 3-[(3,5-di-*t*-butyl-4-hydroxyphenyl)methylen]-7-azaoxindole, the lactose and half the corn starch are mixed; the mixture is then forced through a sieve of 0.5 mm mesh size.

WO 96/16964

PCT/EP95/04247

-43-

Corn starch (10 g) is suspended in warm water (90 ml) and the resulting paste is used to granulate the powder. The granulate is dried, comminuted on a sieve of 1.4 mm mesh size, then the remaining quantity of starch, talc and 5 magnesium stearate are added, carefully mixed and processed into tablets.

Example 19

10 Capsules, each dosed at 0.200 g and containing 20 mg of the active substance can be prepared.

Composition for 500 capsules:


3-[(7-azaindol-3-yl)methylene]-7-azaoxindole	10 g
Lactose	80 g
15 Corn starch	5 g
Magnesium stearate	5 g

This formulation is encapsulated in two-piece hard gelatin capsules and dosed at 0.200 g for each capsule.

- 44 -



CLAIMS


1. A compound of formula (I)



5 wherein

A is benzene, naphthalene, 5,6,7,8,-tetrahydronaphthalene, quinoline, isoquinoline, indole or 7-azaindole;

R₁ is -H, -CN, -SO₃R₄, -SO₂NHR₅, , -COOR₆,
 -CON, -NR₇R₈, -N(CH₂CH₂OH)₂,
 -NHCH₂(CHOH)_nCH₂OH, -NHCONH₂, -NH-C(NH₂)=NH,
 -NHCO(CHOH)_nCH₂OH, , -NHSO₂R₉, -OR₁₀,
 -OCH₂(CHOH)_nCH₂OH, -OOC(CHOH)_nCH₂OH, -OPO(OH)₂, -CH₂NH₂,

10 -C(NH₂)=NH, -CH₂NHC(NH₂)=NH, , -CH₂OH,
 -CH₂OOC(CHOH)_nCH₂OH, -CH₂OPO(OH)₂ or -PO(OH)₂;

R₂ is C₁-C₆ alkyl, halogen, or hydroxy;

R₃ is -H or C₁-C₆ alkyl;

R₄ is -H, C₁-C₆ alkyl or -CH₂(CHOH)_nCH₂OH;

R₅ is -H, C₁-C₆ alkyl, -CH₂(CHOH)_nCH₂OH or -(CH₂)_mNMe₂;

20 R₆ is -H, C₁-C₆ alkyl or -CH₂(CHOH)_nCH₂OH;

WO 96/16964

PCT/EP95/04247

-45-

each of R₁ and R₈ independently is -H or C₁-C₆ alkyl;

R₉ is methyl or tolyl;

R₁₀ is -H, C₁-C₆ alkyl or C₂-C₆ alkanoyl;

Z is >CH₂, >O, >NH or >NCH₂CH₂OH;

5 n is zero or 1;

m is 2 or 3;

p is 1, 2 or 3;

q is zero, 1 or 2;


and the pharmaceutically acceptable salt thereof.

10

2. A compound of formula (I) according to claim 1 wherein:

A is benzene, 5,6,7,8-tetrahydronaphthalene,

quinoline, indole or 7-azaindole;




R₁ is -H, -NH₂, -COOH, -CN, -SO₃H, -SO₂NH₂,




, -COOMe, -N(CH₂CH₂OH)₂,

-NHCH₂CHOHCH₂OH, -NHCONH₂, -NHC(NH₂)=NH, -NHCOCHOHCH₂OH,



, -NHSO₂Me, -OCH₂CHOHCH₂OH, -OOCCH₂OH,

-OOCCHOHCH₂OH, -OH, -OMe, -OPO(OH)₂, -CH₂NH₂, -C(NH₂)=NH,



, -CH₂OH, -OPO(OH)₂, -PO(OH)₂;

20 R₂ is C₁-C₆ alkyl or hydroxy;

R₃ is -H;

q is zero, 1 or 2;

and the azaoxindolylidene substituent is linked to position 1 or 2 when A is naphthalene or 5,6,7,8-

25 tetrahydronaphthalene, to position 4 or 5 when A is

WO 96/16964

PCT/EP95/04247

-46-

quinoline, to position 3 when A is indole or 7-azaindole, whereas the R₁ substituent is linked to the other ring moiety when A is bicyclic, and the pharmaceutically acceptable salts thereof.

5

3. A compound which, when appropriate, may be either a Z or an E-diasteromer or a Z,E-mixture of said diasteromers, selected from a group consisting of:

3-[(3,5-di-tert-butyl-4-hydroxyphenyl)methylene]-7-azaoxindole;

3-[(4-hydroxyphenyl)methylene]-7-azaoxindole;

3-[(4-(2,3-dihydroxypropoxy)phenyl)methylene]-7-azaoxindole;

3-[(4-methoxyphenyl)methylene]-7-azaoxindole;

10 3-[(4-aminophenyl)methylene]-7-azaoxindole;

3-[(4-diethanolaminophenyl)methylene]-7-azaoxindole;

3-[(4-glyceroylamidophenyl)methylene]-7-azaoxindole;

3-[(4-(3-piperidinopropionylamino)phenyl)methylene]-7-azaoxindole;

20 3-[(4-ureidophenyl)methylene]-7-azaoxindole;

3-[(4-mesylaminophenyl)methylene]-7-azaoxindole;

3-[(4-guanidinophenyl)methylene]-7-azaoxindole;

3-[(4-sulfophenyl)methylene]-7-azaoxindole;

3-[(4-N,N-piperazinylsulfamoylphenyl)methylene]-7-

25 azaoxindole;

3-[(4-sulfamoylphenyl)methylene]-7-azaoxindole;

3-[(4-aminomethylphenyl)methylene]-7-azaoxindole;

3-[(4-amidinophenyl)methylene]-7-azaoxindole;

3-[(4-phosphonooxyphenyl)methylene]-7-azaoxindole;

30 3-[(4-carboxyphenyl)methylene]-7-azaoxindole;

3-[(4-carbomethoxyphenyl)methylene]-7-azaoxindole;

WO 96/16964

PCT/EP95/04247

-47-

3-[(4-hydroxymethylphenyl)methylene]-7-azaoxindole;
3-[4-(2,3-dihydroxypropylamino)phenylmethylene]-7-
azaoxindole;
3-[(4-glycoloyloxyphenyl)methylene]-7-azaoxindole;
5 3-[(4-phosphonophenyl)methylene]-7-azaoxindole;
3-[(4-hydroxyethylpiperazin-1-ylmethyl)phenyl
methylene]-7-azaoxindole;
3-[4-(N,N-(4'-hydroxyethyl)piperazinylcarbamoyl)
phenylmethylene]-7-azaoxindole;
10 3-[4-sulfophenylmethylene]-7-azaoxindole sodium salt;
3-[4-aminophenylmethylene]-7-azaoxindole hydrochloride;
3-[4-aminophenylmethylene]-7-azaoxindole trifluoro-
acetate;
15 3-[(3-hydroxy-5,6,7,8-tetrahydronaphth-2-yl)methylene]-
7-azaoxindole;
3-[(1,4-dihydroxy-5,6,7,8-tetrahydronaphth-2-yl)
methylene]-7-azaoxindole;
3-[3-(2,3-dihydroxypropoxy)-5,6,7,8-tetrahydronaphth-2-
yl)methylene]-7-azaoxindole;
20 3-[(3-methoxy-5,6,7,8-tetrahydronaphth-2-yl)methylene]-
7-azaoxindole;
3-[(4-amino-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-
azaoxindole;
3-[(4-diethanolamino-5,6,7,8-tetrahydronaphth-1-yl)
25 methylene]-7-azaoxindole;
3-[(4-glycerylamino-5,6,7,8-tetrahydronaphth-1-yl)
methylene]-7-azaoxindole;
3-[4-(3-piperidinopropionylamino)-5,6,7,8-
tetrahydronaphth-1-yl] methylene]-7-azaoxindole;
30 3-[(4-ureido-5,6,7,8-tetrahydronaphth-1-yl)methylene]-
7-azaoxindole;

WO 96/16964

PCT/EP95/04247

- 48 -

3-[(4-mesylamino-5,6,7,8-tetrahydronaphth-1-yl)
methylene]-7-azaoxindole;

3-[(4-guanidino-5,6,7,8-tetrahydronaphth-1-yl)
methylene]-7-azaoxindole;

5 3-[(4-sulfo-5,6,7,8-tetrahydronaphth-1-yl)methylene]-7-
azaoxindole;

3-[(4-N,N-piperazinylsulfamoyl-5,6,7,8-tetrahydro
naphth-1-yl)methylene]-7-azaoxindole;

3-[(4-sulfamoyl-5,6,7,8-tetrahydronaphth-1-yl)
10 methylene]-7-azaoxindole;

3-[(4-aminomethyl-5,6,7,8-tetrahydronaphth-1-yl)
methylene]-7-azaoxindole;

3-[(4-amidino-5,6,7,8-tetrahydronaphth-1-yl)methylene]-
7-azaoxindole;

15 3-[(4-phosphono-5,6,7,8-tetrahydronaphth-1-yl)
methylene]-7-azaoxindole;

3-[(4-carboxy-5,6,7,8-tetrahydronaphth-1-yl)methylene]-
7-azaoxindole;

3-[(4-carbomethoxy-5,6,7,8-tetrahydronaphth-1-yl)
20 methylene]-7-azaoxindole;

3-[(4-quinolyl)methylene]-7-azaoxindole;

3-[(8-hydroxy-5-quinolyl)methylene]-7-azaoxindole;

3-[(8-sulfo-5-quinolyl)methylene]-7-azaoxindole;

3-[(8-sulfamoyl-5-quinolyl)methylene]-7-azaoxindole;

25 3-[(8-aminomethyl-5-quinolyl)methylene]-7-azaoxindole;

3-[(2-methyl-3-indolyl)methylene]-7-azaoxindole;

3-[(3-indolyl)methylene]-7-azaoxindole;

3-[(5-hydroxy-3-indolyl)methylene]-7-azaoxindole;

3-[(5-methoxy-3-indolyl)methylene]-7-azaoxindole;

30 3-[(5-amino-3-indolyl)methylene]-7-azaoxindole;

WO 96/16964

PCT/EP95/04247

-49-

3-[(5-diethanolamino-3-indolyl)methylene]-7-azaoxindole;
3-[(5-glyceroylamido-3-indolyl)methylene]-7-azaoxindole;
5 3-[(5-(3-piperidinopropionylamino)-3-indolyl)methylene]-7-azaoxindole;
3-[(5-ureido-3-indolyl)methylene]-7-azaoxindole;
3-[(5-mesylamino-3-indolyl)methylene]-7-azaoxindole;
3-[(5-guanidino-3-indolyl)methylene]-7-azaoxindole;
10 3-[(5-sulfo-3-indolyl)methylene]-7-azaoxindole;
3-[(5-N,N-piperazinylsulfamoyl-3-indolyl)methylene]-7-azaoxindole;
3-[(5-sulfamoyl-3-indolyl)methylene]-7-azaoxindole;
3-[(5-aminomethyl-3-indolyl)methylene]-7-azaoxindole;
15 3-[(5-amidino-3-indolyl)methylene]-7-azaoxindole;
3-[(5-phosphono-3-indolyl)methylene]-7-azaoxindole;
3-[(5-carboxy-3-indolyl)methylene]-7-azaoxindole;
3-[(5-carbomethoxy-3-indolyl)methylene]-7-azaoxindole;
3-[(7-azaindol-3-yl)methylene]-7-azaoxindole;
20 3-[(4-hydroxy-7-azaindol-3-yl)methylene]-7-azaoxindole;
3-[(4-amino-7-azaindol-3-yl)methylene]-7-azaoxindole;
3-[(4-(3-piperidinopropionylamino)-7-azaindol-3-yl)methylene]-7-azaoxindole;
3-[(4-ureido-7-azaindol-3-yl)methylene]-7-azaoxindole;
25 3-[(4-sulfo-7-azaindol-3-yl)methylene]-7-azaoxindole;
3-[(4-sulfamoyl-7-azaindol-3-yl)methylene]-7-azaoxindole;
3-[(4-amidino-7-azaindol-3-yl)methylene]-7-azaoxindole;
3-[(4-carboxy-7-azaindol-3-yl)methylene]-7-azaoxindole;
30 and the pharmaceutically acceptable salt of the above
listed compounds.


WO 96/16964

PCT/EP95/04247


-50-

4. A process for obtaining a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, comprising:

5 a) condensation of an aldehyde of formula (II)




wherein A, R₁, R₂ and q are as defined in claim 1, with a compound of formula (III)



10 wherein R₃ is as defined in claim 1; or

b) N-alkylation of a compound of formula (IV)



15 wherein A, R₂, R₃ and q are as defined in claim 1, thus obtaining a compound of formula (I), wherein R₁ is $-N(CH_2CH_2OH)_2$ or $-NHCH_2(CHOH)_nCH_2OH$ and A, R₂, R₃ and q are as defined in claim 1; or

20 c) N-acetylation of a compound of formula (IV), wherein A, R₂, R₃ and q are as defined in claim 1, thus obtaining a compound of formula (I) wherein R₁ is

WO 96/16964

PCT/EP95/04247

-51-

$$-\text{NHCO}(\text{CH}_2)_p\text{-N} \begin{array}{c} \text{C}_6\text{H}_4 \\ | \\ \text{Z} \end{array}$$

$$-\text{NHCO}(\text{CHOH})_n\text{CH}_2\text{OH}$$
 or and A, R₂, R₃,
 n, p, q and Z are as defined in claim 1; or


d) N-sulfonylation of a compound of formula (IV)

5 wherein A, R₂, R₃ and q are as defined in claim 1, thus obtaining a compound of formula (I) wherein R₁ is -NHSO₂R, and A, R₂, R₃, R₉ and q are as defined above; or

10 e) N-amidination of a compound of formula (IV) wherein A, R₂, R₃ and q are as defined in claim 1, thus obtaining a compound of formula (I) wherein R₁ is -NHC(NH₂)=NH and A, R₂, R₃ and q are as defined above; or

15 f) N-carbamoylation of a compound of formula (IV) wherein A, R₂, R₃ and q are as defined in claim 1, thus obtaining a compound of formula (I) wherein R₁ is -NHCONH₂ and A, R₂, R₃ and q are as defined above; or

20 g) O-alkylation of a compound of formula (V)



25 wherein A, R₂, R₃ and q are as defined in claim 1, thus obtaining a compound of formula (I) wherein R₁

WO 96/16964

PCT/EP95/04247

-52-


is $-\text{OCH}_2(\text{CHOH})_n\text{CH}_2\text{OH}$ or $-\text{OR}_{10}$ in which R_{10} is $\text{C}_1\text{-C}_6$ alkyl and A , R_2 , R_3 and q are as defined above; or

h) O-acylation of a compound of formula (V) wherein A ,
 5 R_2 , R_3 and q are as defined in claim 1, thus
 obtaining a compound of formula (I) wherein R_1 is
 $-\text{OOC}(\text{CHOH})_n\text{CH}_2\text{OH}$ or $-\text{OR}_{10}$ in which R_{10} is $\text{C}_2\text{-C}_6$ alkanoyl and A , R_2 , R_3 and q are as defined above;
 or

10

i) O-phosphorylation of a compound of formula (V)
 wherein A , R_2 , R_3 and q are as defined in claim 1,
 thus obtaining a compound of formula (I) wherein R_1
 15 is $-\text{OPO}(\text{OH})_2$ and A , R_2 , R_3 and q are as defined
 above; or

k) esterification of a compound of formula (VI)




20 wherein A , R_2 , R_3 and q are as defined in claim 1,
 thus obtaining a compound of formula (I) wherein R_1
 is $-\text{COOR}_6$ and A , R_2 , R_3 and q are as defined above;
 or

l) ammonia addition of a compound of formula (VII)

WO 96/16964

PCT/EP95/04247


-53-



wherein A, R₂, R₃ and q are as defined in claim 1, thus obtaining a compound of formula (I) wherein R₁ is -C(NH₂)=NH and A, R₂, R₃ and q are as defined above; or

5

m) amination of a compound of formula (VIII)



wherein A, R_2 , R_3 , and q are as defined in claim 1,
thus obtaining a compound of formula (I) wherein R,

10

is $-\text{CH}_2\text{NH}_2$ or  and A, R₂, R₃ and q are as defined above;

15

and/or conversion of a compound of formula (I) into another compound of formula (I) and/or optional salification of a compound of formula (I) or conversion of a salt into the corresponding free compound of formula (I) and/or, if desired, separation of a mixture of isomers into the single isomers.

20

5. A pharmaceutical composition containing a suitable carrier and/or diluent and, as an active principle, a

WO 96/16964

PCT/EP95/04247

-54-

compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof.

6. A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, for use as a tyrosine kinase inhibitor.
5
7. Use of a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use as a tyrosine kinase inhibitor.
10
8. A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, for use as an antiproliferative agent.
15
9. Use of a compound of formula (I), according to claim 1, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use as antiproliferative agent.
20
10. A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, for use as an anti-cancer agent or in the treatment of coronary artery disease or in the control of angiogenesis.
25
11. Use of a compound of formula (I), according to claim 1, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use as anti-cancer agent or in the treatment of coronary artery disease or in the control of angiogenesis.
30

WO 96/16964

PCT/EP95/04247

-55-

12. Products containing a compound of formula (I),
according to claim 1, or a pharmaceutically acceptable
salt thereof, and an anti-tumor agent as a combined
preparation for simultaneous, separate or sequential
5 use in anti-cancer therapy.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/EP 95/04247

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07D471/04 C07D519/00 A61K31/435 // (C07D471/04, 221:00, 209:00), (C07D519/00, 471:00, 471:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHEDMinimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,94 14808 (FARMITALIA CARLO ERBA) 7 July 1994 see claims 1,6 -----	1,5,6

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- 'A' document member of the same patent family

1

Date of the actual completion of the international search

Date of mailing of the international search report

26 February 1996

11.03.96

Name and mailing address of the ISA
 European Patent Office, P.O. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. No.

PCT/EP 95/04247

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9414808	07-07-94	AU-B-	5810594	19-07-94
		CA-A-	2126228	07-07-94
		CN-A-	1093707	19-10-94
		EP-A-	0626963	07-12-94
		FI-A-	943838	19-08-94
		HU-A-	67431	28-04-95
		JP-T-	7504208	11-05-95
		NZ-A-	259330	21-12-95
		PL-A-	304894	09-01-95
		US-A-	5397787	14-03-95

